EU Advisory Panel Clears Sanofi’s Jevtana But Wants to Review Multaq’s Liver Risks
This article was originally published in The Pink Sheet Daily
Executive Summary
Sanofi-Aventis' cabazitaxel receives a positive opinion from the EU's scientific advisory committee, but the benefit/risk balance of the French company's anti-arrhythmic, Multaq, needs to be reviewed.
You may also be interested in...
EMA's Restriction Of Multaq Indication Could Spell Death Knell For The Drug In Europe
While giving it a positive risk/benefit balance, EMA says other anti-arrhythmic medicines should be considered before Sanofi's Multaq, potentially heralding its demise in Europe.
EMA's Restriction Of Multaq Indication Could Spell Death Knell For The Drug In Europe
While giving it a positive risk/benefit balance, EMA says other anti-arrhythmic medicines should be considered before Sanofi's Multaq, potentially heralding its demise in Europe.
Five Positive Opinions From EU's CHMP Brightens Up The New Year
New molecular entities from Valeant/GSK, Eisai, Sanofi and Novartis make the grade for the EU's scientific panel at its January meeting.